文献速递鼻科

与SNOT协同的变应性鼻炎评估工具的验证

Validation of an Allergic Rhinitis Instrument That Synergizes With the Sino-Nasal Outcome Test.
PubMed 文献 · Int Forum Allergy Rhinol · 2026-08-04

本研究评估了一种与SNOT-22/26/29协同的新型变应性鼻炎专用评估工具,在3566例连续应答中行因子分析,598例有过敏检测。结果显示该工具用26个问题可同时且区分评估AR与CRS,无重复内容,并具区分效度、聚合效度、组内信度和反应度。

要点

  • 该AR专用工具仅需26题即可同时且区分评估AR与CRS,减少冗余与应答负担。
  • 工具可区分过敏检测阳性与阴性患者(均值差1.22,95%CI 0.36-2.09)。
  • 5、6、7条目版本可独立或与SNOT其他域联合用于AR评估。

核心结论

  • 该协同方法为同时且区分评估AR与CRS提供了新颖、简洁、高效且经验证的途径。

研究设计与样本

  • 前瞻性纳入完成所提出的AR专用与SNOT变体、MiniRQLQ及一般健康评估的患者,对3566例连续应答行因子分析,其中598例有过敏检测。

主要发现

  • AR专用工具以26个问题支持AR与CRS的同时且区分评估,而SNOT-22+MiniRQLQ需46个问题且存在重复内容。
  • 工具可区分过敏检测阳性与阴性患者,均值差1.22(95%CI 0.36-2.09)。
  • 与MiniRQLQ的聚合效度Spearman rho为0.346-0.736,与PROMIS的Spearman rho为-0.118至-0.264。
  • 组内信度Cohen kappa为0.802-0.829、Spearman rho为0.918-0.935;反应度均值差为-0.28(95%CI -0.52至-0.05)。
  • 5、6、7条目版本可作为AR专用评估,独立使用或与SNOT其他域联合。

临床怎么用

  • 临床可用该26题AR专用工具与SNOT联合,同时且区分评估AR与CRS,减少重复提问与应答负担。
  • 根据场景可选用5、6或7条目版本独立评估AR,或与SNOT其他域联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) frequently co-occur with shared symptomatology, such that evaluating both entities concurrently yet discretely is of help. Previously validated options, however, may require more than 45 questions and introduce redundant content at each administration. We thus assessed whether a novel AR-specific instrument, which has synergy with the Sino-Nasal Outcome Test (SNOT-22/26/29) used in CRS, is valid for research and clinical care. METHODS: Patients who prospectively completed the proposed AR-specific and SNOT instrument variations, the Mini-Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ), and a general health assessment were included. Factor analysis was performed on 3566 consecutive responses, and 598 patients had allergy testing. Discriminant validity was assessed among patients with positive and negative allergy test results. Convergent validity was assessed using the MiniRQLQ and general health scores. Intra-rater reliability and responsiveness to change were quantified. RESULTS: The AR-specific test supported concurrent yet discrete evaluation of AR and CRS with 26 questions (instead of 46 from SNOT-22+MiniRQLQ) and no repetition (SNOT22+RCAT/RQLQ repeat query content, e.g., patients asked about sneezing twice). The AR instrument discriminated between patients with positive or negative allergy tests (difference in means 1.22 [95% CI: 0.36-2.09]). Convergence with MiniRQLQ (Spearman's rho: 0.346-0.736) and PROMIS (Spearman's rho: -0.118 to -0.264) was observed. Intra-rater reliability (Cohen kappa: 0.802-0.829; Spearman's rho: 0.918-0.935) and responsiveness to change (difference in means -0.28 [95% CI: -0.52 to -0.05]) were demonstrated. CONCLUSIONS: This synergistic approach offers a novel, concise, efficient, and validated method to assess AR and CRS concurrently yet discretely. KEY POINTS: This allergic rhinitis instrument offers a novel, concise, efficient, and validated method to assess AR and chronic rhinosinusitis (CRS) discretely yet concurrently with the Sino-Nasal Outcome Test, while reducing redundancy and response burden. The allergic rhinitis-specific items demonstrate internal consistency, discriminant and convergent validity, strong intra-rater reliability, and responsiveness to clinical change. Five-, six-, and seven-item versions can function as AR-specific assessments that can be used independently or alongside other Sino-Nasal Outcome Test domains.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Zhang SK, Gilani S, Zhou A, et al. Validation of an Allergic Rhinitis Instrument That Synergizes With the Sino-Nasal Outcome Test. Int Forum Allergy Rhinol. 2026. PMID: 42550565. doi:10.1002/alr.70227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。